---
title: "Manulife strengthens cooperation with CUHK Medical Centre to incorporate fragmented technology into treatment options"
description: "Manulife has strengthened its cooperation with The Chinese University of Hong Kong (CUHK) Medical Centre to incorporate fragmentation technology into its health insurance plans, providing innovative t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/230953764.md"
published_at: "2025-03-07T08:31:26.000Z"
---

# Manulife strengthens cooperation with CUHK Medical Centre to incorporate fragmented technology into treatment options

> Manulife has strengthened its cooperation with The Chinese University of Hong Kong (CUHK) Medical Centre to incorporate fragmentation technology into its health insurance plans, providing innovative therapies for cancer patients. This technology is an FDA-approved non-invasive treatment aimed at providing efficient options for liver cancer patients. The service will be implemented once the technology is available to the public, and patients will need to participate in clinical trials to monitor outcomes. Manulife has established a partnership with CUHK Medical Centre since 2021 to provide medical consultation and pre-approval services without co-payment

Manulife strengthens cooperation with CUHK Medical Centre to incorporate tissue fragmentation technology into treatment options

Manulife announced the strengthening of its strategic partnership with the Chinese University of Hong Kong Medical Centre, incorporating the innovative tissue fragmentation technology into its comprehensive "Healthcare Specialist Support Service" designed for clients with confirmed or suspected cancer under Manulife's designated medical insurance plans. This service will commence once the tissue fragmentation technology becomes available for public use at CUHK Medical Centre, at which point relevant patients will need to participate in clinical trials for close monitoring and evaluation of clinical outcomes.

Tissue fragmentation technology is an FDA-approved technique that provides a non-invasive, painless, and efficient treatment option for liver cancer patients. The Li Ka Shing Foundation previously introduced this treatment technology to medical institutions in Hong Kong through donations. The coverage for all Manulife medical insurance plan clients includes tissue fragmentation technology, further enhancing protection for clients.

In 2021, Manulife established a strategic partnership with CUHK Medical Centre to offer eligible clients a free personal medical consultation. Subsequently, in 2023, both parties further expanded their cooperation, with Manulife providing pre-approval services for over 300 all-inclusive medical packages offered by the hospital, including endoscopic examination procedures and surgical procedures

### Related Stocks

- [MFC.US - Manulife Financial](https://longbridge.com/en/quote/MFC.US.md)
- [00945.HK - MANULIFE-S](https://longbridge.com/en/quote/00945.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Manulife Brief: Announcing Normal Course Issuer Bid, Representing About 2.5% of Issued and Outstanding Common Shares | Manulife Brief: Announcing Normal Course Issuer Bid, Representing About 2.5% of Issued and Outstanding Common Shares | [Link](https://longbridge.com/en/news/276381436.md) |
| Canada's Manulife Q4 core earnings rise 5% | Canada's Manulife reported a 5% year-over-year increase in Q4 core earnings, with adjusted EPS surpassing analyst expect | [Link](https://longbridge.com/en/news/275667029.md) |
| AgelessRx Expands Access to Multi-Cancer Early Detection Solutions, in Honor of Cancer Prevention Month | AgelessRx is expanding access to its multi-cancer early detection solutions in honor of Cancer Prevention Month. This in | [Link](https://longbridge.com/en/news/276180967.md) |
| AbbVie Says FDA Approves Cancer Combo Therapy | AbbVie Says FDA Approves Cancer Combo Therapy | [Link](https://longbridge.com/en/news/276427063.md) |
| 10:02 ETThe Center for Cancer and Blood Disorders Revolutionizes the Delivery of CAR-T Cancer Treatments for Texas Patients | The Center for Cancer and Blood Disorders has launched a program to deliver CAR-T therapy in community practices across  | [Link](https://longbridge.com/en/news/276139832.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.